PeptiDream×Nxera Pharma
Different ways of making money, on the same scale.
Same yardstick
| Metric | PeptiDreamFY ending Dec 2024 | Nxera PharmaFY ending Dec 2023 |
|---|---|---|
| Revenue | ¥46.7B | ¥12.8B |
| COGS ratio | 26.1% | — |
| Operating margin | 45.2% | — |
| Net margin | 32.2% | -56.3% |
| FCF margin | 46.3% | — |
Highlighted = best value for that metric
Compare industry percentiles by axis
Each row uses the same 0–100 scale. Dots show each company's rank within its primary industry.
- PeptiDreamPrimary industry: Biotech & Regenerative Medicine
- Nxera PharmaPrimary industry: Biotech & Regenerative Medicine
CompanyRank
Revenue growth
- PeptiDreamN/A
- Nxera PharmaN/A
- PeptiDream
Profitability
- PeptiDream91.76 peers
- Nxera PharmaN/A
- PeptiDream
Cash conversion
- PeptiDream62.54 peers
- Nxera PharmaN/A
- PeptiDream
Efficiency
- PeptiDream64.37 peers
- Nxera Pharma7.17 peers
- PeptiDream
Financial strength
- PeptiDreamN/A
- Nxera PharmaN/A
- PeptiDream
Each dot is a company's percentile within its primary industry; peer groups may differ. Missing axes are labeled as unavailable. No combined score is calculated, and industry rank is not an investment recommendation.
Money flows side by side
Chart height is proportional to revenue.
PeptiDream¥46.7B · keeps ¥45 per ¥100
Nxera Pharma¥12.8B
※ Cost of revenue is not disclosed; expenses are combined
※ Operating income is not disclosed; the chart goes straight to pretax income including investment gains
Analyze this page with AI
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.